Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand

Sia Daneshmand, MD, joins the show to review 2 studies on the use of erdafitinib for the treatment of non-muscle invasive bladder cancer, including the THOR-2 trial investigating erdafitinib versus intravesical chemotherapy in patients who received BCG therapy and recurred with high-risk NMIBC. Dr. Daneshmand is the director of urologic oncology at the Keck School of Medicine, University of Southern California, Los Angeles.